U.S. stock night market volatility: Butterfly Network rose 11.11% in the night market

U.S. Stock Night Market Movements Butterfly Network rose 11.11% in the night market. According to recent key news: On September 19, Butterfly Network was listed among the top global health technology companies for 2025. This honor was jointly published by TIME and Statista Inc., recognizing the company's innovative contributions to healthcare. This news drove the stock price up by 11.11%. The health technology industry is performing strongly. Stocks with High Trading Volume in the Industry Intuitive Surgical rose 0.15% in the night market. According to recent key news: On September 18, Intuitive Surgical expects a 17% increase in the number of da Vinci surgeries this year, but gross margins are expected to decline by one percentage point due to tariff impacts. Although the stock price has fallen this year, it is still trading at a high price-to-earnings ratio, indicating long-term investment potential. On September 17, investors held an optimistic view of Intuitive Surgical, with inflows of funds showing strong market confidence. On September 16, analysts rated Intuitive Surgical as hold, with a target price of $485, reflecting a cautious market attitude towards its growth potential. The industry has significant growth potential, and tariff impacts need to be monitored. TransMedics rose 0.24% in the night market. Based on recent important news: On September 19, TransMedics' platform aligns with HHS goals to enhance organ availability and utilization, and the company is expected to gain significant market share. Jennings gave a buy rating, and Evercore ISI also gave a buy rating with a target price of $155. This news drove the stock price up. On September 17, TransMedics' growth expectations are strong, with profit margins steadily improving. Although there may be fluctuations in the short term, growth and profit margins will remain strong in 2026, driving the stock price higher. On September 16, TransMedics had an annualized return of 48.66% over the past five years, outperforming the market, with a market capitalization of $3.9 billion, demonstrating the company's strong market performance. The medical industry has significant growth potential, and volatility risks need to be monitored. ResMed rose 0.54% in the night market. Based on recent key news: On September 19, ResMed's stock price rose to AUD 41.910, reaching the highest point since September 10. Citi raised its target price from AUD 49 to AUD 51, expecting the company to increase its profit margin from 60% in fiscal year 2025 to 63% in fiscal year 2027. This drove the stock price up. Data source: LSEG. On September 18, Citigroup analyst Laura Sutcliffe initiated coverage on ResMed with a buy rating and announced a target price of $330. This further enhanced market confidence in the stock. Data source: Citigroup On September 17, ResMed announced that it will participate in the Bank of America Global Healthcare Conference to be held in London on September 23, 2025. This news may have a positive impact on the stock price. Data source: GlobeNewswire. The medical technology industry is performing strongly